These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15059263)

  • 1. Measuring effectiveness of drugs in observational databanks: promises and perils.
    Krishnan E; Fries JF
    Arthritis Res Ther; 2004; 6(2):41-4. PubMed ID: 15059263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness.
    Wolfe F; Michaud K
    Rheumatology (Oxford); 2005 Dec; 44 Suppl 4():iv18-iv22. PubMed ID: 16306476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remission in early rheumatoid arthritis.
    Ma MH; Scott IC; Kingsley GH; Scott DL
    J Rheumatol; 2010 Jul; 37(7):1444-53. PubMed ID: 20516031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can observational studies replace or complement experiment?
    van der Linden S; Goldsmith CH; Woodcock J; Nassonova V
    J Rheumatol Suppl; 1994 Sep; 41():57-61. PubMed ID: 7799388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.
    Nandi P; Kingsley GH; Scott DL
    Curr Opin Rheumatol; 2008 May; 20(3):251-6. PubMed ID: 18388514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active-comparator design and new-user design in observational studies.
    Yoshida K; Solomon DH; Kim SC
    Nat Rev Rheumatol; 2015 Jul; 11(7):437-41. PubMed ID: 25800216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II.
    Cox E; Martin BC; Van Staa T; Garbe E; Siebert U; Johnson ML
    Value Health; 2009; 12(8):1053-61. PubMed ID: 19744292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicals.
    Boers M
    Ann Rheum Dis; 2010 Jan; 69(1):4-6. PubMed ID: 20007620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic monitoring of disease activity using an outcome measure improves outcomes in rheumatoid arthritis.
    Katchamart W; Bombardier C
    J Rheumatol; 2010 Jul; 37(7):1411-5. PubMed ID: 20436069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring the efficacy and effectiveness of rheumatoid arthritis therapy: time to change our thinking and adopt a new model.
    Wolfe F; Caplan L; Michaud K
    J Rheumatol; 2004 Dec; 31(12):2317-9. PubMed ID: 15570626
    [No Abstract]   [Full Text] [Related]  

  • 11. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach.
    Devine EB; Alfonso-Cristancho R; Sullivan SD
    Pharmacotherapy; 2011 Jan; 31(1):39-51. PubMed ID: 21182357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In quest of the holy grail: efficacy versus effectiveness in rheumatoid arthritis.
    Suarez-Almazor ME
    J Rheumatol; 2002 Feb; 29(2):209-11. PubMed ID: 11838836
    [No Abstract]   [Full Text] [Related]  

  • 13. Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa?
    Pincus T; Sokka T
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii32-ii39. PubMed ID: 15479869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drugs for rheumatoid arthritis.
    Roberts LJ
    N Engl J Med; 2004 Dec; 351(25):2659-61; author reply 2659-61. PubMed ID: 15602032
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.
    Zink A; Strangfeld A; Schneider M; Herzer P; Hierse F; Stoyanova-Scholz M; Wassenberg S; Kapelle A; Listing J
    Arthritis Rheum; 2006 Nov; 54(11):3399-407. PubMed ID: 17075823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: part 6. Systematic reviews and meta-analyses of observational studies.
    Manchikanti L; Datta S; Smith HS; Hirsch JA
    Pain Physician; 2009; 12(5):819-50. PubMed ID: 19787009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized controlled trials of rheumatoid arthritis registered at ClinicalTrials.gov: what gets published and when.
    Khan NA; Singh M; Spencer HJ; Torralba KD
    Arthritis Rheumatol; 2014 Oct; 66(10):2664-74. PubMed ID: 25154608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy.
    Bijlsma JW; van der Goes MC; Hoes JN; Jacobs JW; Buttgereit F; Kirwan J
    Ann N Y Acad Sci; 2010 Apr; 1193():123-6. PubMed ID: 20398017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Confounders in Comparative Effectiveness Studies From Secondary Databases.
    Franklin JM; Schneeweiss S; Solomon DH
    Am J Epidemiol; 2017 Mar; 185(6):474-478. PubMed ID: 28399570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials: how to cope with medical needs, ethics and timelines.
    Rubbert-Roth A; Burmester GR
    Ann Rheum Dis; 2010 Jan; 69(1):1-3. PubMed ID: 20007619
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.